Abstract
Over the last several years, direct to consumer (DTC) genetic testing has received increasing attention in the public, healthcare and academic realms. DTC genetic testing companies face considerable criticism and scepticism, particularly from the medical and genetic counseling community. This raises the question of what specific aspects of DTC genetic testing provoke concerns, and conversely, promises, for genetic counselors. This paper addresses this question by exploring DTC genetic testing through an ethical lens. By considering the fundamental ethical approaches influencing genetic counseling (the ethic of care and principle-based ethics) we highlight the specific ethical concerns raised by DTC genetic testing companies. Ultimately, when considering the ethics of DTC testing in a genetic counseling context, we should think of it as a balancing act. We need careful and detailed consideration of the risks and troubling aspects of such testing, as well as the potentially beneficial direct and indirect impacts of the increased availability of DTC genetic testing. As a result it is essential that genetic counselors stay informed and involved in the ongoing debate about DTC genetic testing and DTC companies. Doing so will ensure that the ethical theories and principles fundamental to the profession of genetic counseling are promoted not just in traditional counseling sessions, but also on a broader level. Ultimately this will help ensure that the public enjoys the benefits of an increasingly genetic-based healthcare system.
Similar content being viewed by others
References
ACMG (2004). ACMG statement on direct-to-consumer genetic testing. Genetics in Medicine, 6(1), 60.
Angrist, M. (2009). We are the genes we’ve been waiting for: rational responses to the gathering storm of personal genomics. The American Journal of Bioethics, 9(6), 30–31.
Armstrong, K., Micco, E., Carney, A., Stopfer, J., & Putt, M. (2005). Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA: The Journal of the American Medical Association, 293(14), 1729–1736.
Beauchamp, T., & Childress, J. (2009). Principles of biomedical ethics. USA: Oxford University Press.
Bloss, C., Ornowski, L., Silver, E., Cargill, M., Vanier, V., Schork, N., et al. (2010). Consumer perceptions of direct to consumer personalized genomic risk assessments. Genetics in Medicine, 12(9), 556–566.
Bloss, C., Schork, N., & Topol, E. (2011). Effect of direct to consumer genomewide profiling to assess disease risk. The New England Journal of Medicine, 364(6), 524–534.
Bloss, C. S., Topol, E. J., & Schork, N. J. (2011). Association of direct-to-consumer genome-wide disease risk estimates and self-reported disease. Genetic Epidemiology. doi:10.1002/gepi.20664.
Brice, P. (2010). Current DTC genetic testing market smaller than expected. http://www.phgfoundation.org/news/5658/. Accessed May 30 2011.
Burke, W., & Psaty, B. (2007). Personalized medicine in the era of genomics. JAMA: Journal of the American Medical Association, 298(14), 1682–1684.
Burke, S., Martyn, M., Stone, A., Bennett, C., Thomas, H., & Farndon, P. (2009). Developing a curriculum statement based on clinical practice: genetics in primary care. British Journal of General Practice, 59(559), 99–103.
Caulfield, T. (2009). Direct to consumer genetics and health policy: a worst-case scenario? The American Journal of Bioethics, 9(6 & 7), 48–50.
Daniels, N. (2001). Justice, health, and healthcare. American Journal of Bioethics, 1(2), 2–16.
Geransar, R., & Einsiedel, E. (2008). Evaluating online direct to consumer marketing of genetic tests: informed choices or buyers beware? Genetic testing, 12(1), 13–23.
Gillon, R. (1986). Philosophical Medical Ethics. Wiley and Son.
Giovanni, M. A., Fickie, M. R., Lehmann, L. S., Green, R. C., Meckley, L. M., Veenstra, D., et al. (2010). Health-care referrals from direct to consumer genetic testing. Genetic Testing and Molecular Biomarkers, 14(6), 817–819.
Gollust, S. E., Hull, S. C., & Wilfond, B. S. (2002). Limitations of direct to consumer advertising for clinical genetic testing. JAMA: Journal of the American Medical Association, 288(14), 1762–1767.
Green, R. C., Roberts, J. S., Cupples, L. A., Relkin, N. R., Whitehouse, P. J., Brown, T., et al. (2009). Disclosure of APOE genotype for risk of Alzheimer’s disease. The New England Journal of Medicine, 361(3), 245–254.
Guttmacher, A. E., Porteous, M. E., & McInerney, J. D. (2007). Educating health-care professionals about genetics and genomics. Nature Reviews Genetics, 8(2), 151–157.
Hall, M., & Olopade, O. I. (2005). Confronting genetic testing disparities. JAMA: The Journal of the American Medical Association, 293(14), 1783–1785.
Headings, V. (1997). Revisiting foundations of autonomy and beneficence in genetic counseling. Genetic Counseling, 8(4), 291–294.
Heshka, J. T., Palleschi, C., Howley, H., Wilson, B., & Wells, P. S. (2008). A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genetics in Medicine, 10(1), 19–32.
Hock, K. T., Christensen, K. D., Yashar, B. M., Roberts, J. S., Gollust, S. E., & Uhlmann, W. R. (2011). Direct to consumer genetic testing: an assessment of genetic counselors’ knowledge and beliefs. Genetics in Medicine, 13(4), 325–332.
Howard, H., & Borry, P. (2009). Personal genome testing: do you know what you are buying? The American Journal of Bioethics, 9(6), 11–34.
Hsu, A., Mountain, J., Wojcicki, A., & Avey, L. (2009). A pragmatic consideration of ethical issues relating to personal genomics. The American Journal of Bioethics, 9(6), 1–2.
Hudson, K., Javitt, G., Burke, W., & Byers, P. (2007). ASHG statement on direct to consumer genetic testing in the United States. American Journal of Human Genetics, 81(3), 635–637.
Hunter, A. G. W., Sharpe, N., Mullen, M., & Meschino, W. S. (2001). Ethical, legal, and practical concerns about recontacting patients to inform them of new information: the case in medical genetics. American Journal of Medical Genetics, 103(4), 265–276.
Janssens, A. C., Gwinn, M., Bradley, L. A., Oostra, B. A., van Duijn, C. M., & Khoury, M. J. (2008). A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. American Journal Human Genetics, 82(3), 593–599.
Jonsen, A. R. (1986). Casuistry and clinical ethics. Theoretical Medicine and Bioethics, 7(1), 65–74.
Jordens, C., Kerridge, I., & Samuel, G. (2009). Direct to consumer personal genome testing: the problem is not ignorance - it is market failure. The American Journal of Bioethics, 9(6), 13–14.
Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Brody, L. C., & Baxevanis, A. D. (2010). Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. Journal of Medical Internet Research, 12(3), e41.
Karns, L., Roche, M., & Yashar, B. (2005). An ethics casebook for genetic counselors, 2nd Edition: Ethical discourse for the practice of genetic counseling. New York: Springer.
Marchant, G., Milligan, R., & Wilhelmi, B. (2006). Legal pressures and incentives for personalized medicine. Personalized Medicine, 3(4), 391–397.
McBride, C. M., Alford, S. H., Reid, R. J., Larson, E. B., Baxevanis, A. D., & Brody, L. C. (2009). Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genetics in Medicine, 11(8), 582–587.
McGuire, A., & Burke, W. (2008). An unwelcome side effect of direct to consumer personal genome testing: raiding the medical commons. Journal of the American Medical Association, 300(22), 2669–2671.
McGuire, A., Diaz, C., Hilsenbeck, S., & Wang, T. (2009). Social networkers’ attitudes toward direct to consumer personal genome testing. The American Journal of Bioethics, 9(6), 3–10.
Miller, R. (1996). Casuistry and modern ethics: A poetics of practical reasoning. Chicago: University of Chicago Press.
NSGC (2006). Code of Ethics. http://www.nsgc.org/Advocacy/NSGCCodeofEthics/tabid/155/Default.aspx. Accessed May 20, 2011.
Offit, K. (2008). Genomic profiles for disease risk: predictive or premature? JAMA: Journal of the American Medical Association, 299(11), 1353–1355.
Offit, K., Groeger, E., Turner, S., Wadsworth, E. A., & Weiser, M. A. (2004). The“ duty to warn” a patient’s family members about hereditary disease risks. JAMA: The Journal of the American Medical Association, 292(12), 14691473.
Salkin, A. (2008). When in Doubt, Spit It Out. (Sep 14th). New York Times.
Schmerler, S. (1999). Ethical and legal issues. In D. Baker, J. Schuette, & W. Uhlmann (Eds.), A guide to genetic counseling. New York: Wiley and Sons.
Sirovich, B., Woloshin, S., & Schwartz, L. (2011). Too little? Too much? Primary care physicians’ views on us health care a brief report. Archives of Internal Medicine, 171(17), 1582–1585.
Wade, C. H., & Wilfond, B. S. (2006). Ethical and clinical practice considerations for genetic counselors related to direct to consumer marketing of genetic tests. Journal of Medical Genetics, 142(4), 284–292.
Wasson, K., Cook, E., & Helzlsouer, K. (2006). Direct to consumer online genetic testing and the four principles: an analysis of the ethical issues. Ethics and Medicine, 22(2), 83–91.
Weil, J. (2000). Psychosocial genetic counseling. USA: Oxford University Press.
Weil, J. (2003). Psychosocial genetic counseling in the post-nondirective era: a point of view. Journal of Genetic Counseling, 12(3), 199–211.
Williams, M. (2007). Insurance coverage for pharmacogenomic testing in the USA. Personalized Medicine, 4(4), 479–487.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hawkins, A.K., Ho, A. Genetic Counseling and the Ethical Issues Around Direct to Consumer Genetic Testing. J Genet Counsel 21, 367–373 (2012). https://doi.org/10.1007/s10897-012-9488-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-012-9488-8